What are the best treatments for Hurler Syndrome MPS1H?

The primary treatment for Hurler Syndrome (MPS1H) is Hematopoietic Stem Cell Transplantation (HSCT), which is most effective when performed as early as possible, ideally before age two. This is often supplemented by lifelong Enzyme Replacement Therapy (ERT) using laronidase (Aldurazyme) to manage systemic symptoms and support the patient's quality of life.

What are the primary medical treatments for Hurler Syndrome (MPS1H)?

For patients with Hurler Syndrome (MPS1H), the standard of care centers on replacing the missing alpha-L-iduronidase enzyme. Hematopoietic Stem Cell Transplantation (HSCT) is the gold standard for addressing neurological progression by providing a donor source of the enzyme. Additionally, Enzyme Replacement Therapy (ERT) with laronidase (Aldurazyme) is utilized to reduce glycosaminoglycan (GAG) accumulation in tissues, which helps improve respiratory function, joint mobility, and cardiac health.

What supportive and non-pharmacological care is required?

Because Hurler Syndrome (MPS1H) affects multiple organ systems, a multidisciplinary approach is essential to manage the disease's complexity. Non-pharmacological interventions are critical for maintaining mobility and daily function:

• Physical Therapy: Essential for managing joint contractures and maintaining muscle strength.


• Occupational Therapy: Focuses on adapting daily tasks to support independence.


• Surgical Intervention: Common procedures include carpal tunnel release, hernia repairs, and adenotonsillectomy to improve airway obstruction.


• Audiology and Ophthalmology: Regular monitoring for hearing loss and corneal clouding is vital.

Which specialists should be on the care team?

Managing Hurler Syndrome (MPS1H) requires a coordinated team of experts. Key specialists typically include a metabolic geneticist, a pediatric hematologist/oncologist, a cardiologist, an orthopedist, a neurologist, and a speech-language pathologist.

Are there emerging therapies for Hurler Syndrome (MPS1H)?

Research into Hurler Syndrome (MPS1H) is evolving rapidly. Current clinical trials are investigating gene therapy, which aims to introduce a functional copy of the IDUA gene into the patient's cells to provide a permanent source of the enzyme. These experimental approaches represent the next frontier in treating the multisystemic manifestations of the disease.

Next steps

• Consult with a metabolic specialist at a center of excellence to establish a personalized care plan.


• Join the DiseaseMaps.org community to connect with other families navigating the challenges of Hurler Syndrome (MPS1H).


• Visit ClinicalTrials.gov to search for ongoing research opportunities for MPS1H.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare provider for personalized diagnosis and treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hurler syndrome


• Orphanet: Mucopolysaccharidosis type 1H


• National MPS Society: MPS I treatment guidelines


• OMIM (Online Mendelian Inheritance in Man): IDUA gene entry